Precision Therapeutics Assesses Multi-Gene Predictors of Breast Cancer Chemo Response
NEW YORK (GenomeWeb News) – Rosetta Genomics announced after the close of the market on Tuesday that it has revised its co-marketing deal with Precision Therapeutics.
NEW YORK (GenomeWeb News) – Med BioGene today announced it has amended its commercialization agreement with Precision Therapeutics for Med Bio's LungExpress Dx test.
NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a deal with Precision Therapeutics to co-market Rosetta's miRview mets2 assay.
Precision Therapeutics' BioSpeciFx
Med BioGene's shareholders have approved the deal, which gives Precision rights to commercialize Med BioGene's gene expression-based test for early stage non-small-cell lung cancer.
Precision Therapeutics made an improved offer, matching the upfront payment offered by Signal Genetics to license the LungExpress Dx technology.
The new offer comes a month after Signal filed suit against Med BioGene for negotiating a licensing deal for the LungExpress Dx test with Precision Therapeutics.
Precision Therapeutics has gained exclusive rights to the LungExpress Dx test.
Signal filed its suit against Med BioGene earlier this month alleging a breach of agreement, violation of a confidentiality agreement, and misuse of proprietary information, among other charges.
Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.
Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.
The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.
In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.